The clinical presentation and the biochemical and molecular genetic findings are described in a 13 year old Chinese boy with MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes). The diagnosis was initially suspected because of the characteristic clinical features and the strong family history of convulsions. Using polymerase chain reaction-restriction enzyme analysis, the heteroplasmic nt3243 A-G mutation in mtDNA of peripheral blood leucocytes and a muscle sample was demonstrated. The oligosymptomatic relatives were then screened by this method and the degree of heteroplasmy was analysed. This appears to be the first report of a MELAS family in Hong Kong with this described mutation. Molecular genetic techniques are advantageous in the diagnosis of MELAS.
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is one of the maternally inherited mitochondrial diseases and was first described by Pavlakis et all in 1984. For many years, the diagnosis was based mainly on clinical features. Subsequent studies showed that this disease was usually associated with respiratory chain enzyme defects, particularly of NADH dehydrogenase (complex I). In 1990, Goto et al' identified a point mutation in mitochondrial DNA of a MELAS patient, with nt3243 A-+G mutation in the transfer RNAL(UUR) gene. This mutation was subsequently found in over 80% of MELAS patients and their oligosymptomatic relatives.3 In this report, we described a family segregating this mutation. Using molecular genetic techniques we have screened 10 family members and confirmed the diagnosis in those affected. To the best of our knowledge, this is the first MELAS family with this documented mutation in Hong Kong.
Case report
The patient (III1) was a 13 year old Chinese boy with a normal prenatal, perinatal, and developmental history. He was otherwise well until the age of 10 years, when he experienced intermittent headache and lethargy. At 12 years of age, he was admitted to hospital with repeated generalised clonic convulsions and phenobarbitone was started. Three months later he was readmitted for severe migraine over the left frontal region, vomiting, and focal convulsion followed by transient right hemiparesis and right homonymous hemianopia. He also had dysphasia and mental deterioration. An electroencephalogram (EEG) revealed diffuse slow waves with left mid-temporal and central epileptiform discharges. Bilateral basal ganglia calcification was evident on computerised tomography (CT). Magnetic resonance imaging (MRI) of the brain was performed after the first stroke-like episode and showed increased signal intensity in T2 weighted images in the left temporal and parieto-occipital areas. The deproteinated blood lactate concentration was 4-8 mmol/l (normal: 0-5-1 3 mmol/1) and pyruvate was 188 Htmol/l (normal: 45-80 gmol/l), with a lactate/pyruvate ratio of 25-5 (normal: [6] [7] [8] [9] [10] [11] [12] [13] [14] . The results of all other serum laboratory tests were normal. A biopsy obtained from the right quadriceps muscle showed "ragged red fibres" in the modified Gomori trichrome stain and high succinate dehydrogenase (SDH) and nicotinamide adenine dinucleotide-tetrazolium reductase (NADH-TR) activities. Electron microscopy revealed aggregates of giant mitochondria with abnormal cristae and intramatrical electrondense granules. The patient was treated with carbamazepine, phenytoin, thiamine, riboflavin, coenzyme Ql,, and prednisone with apparent beneficial effect.
The patient had a strong family history of similar illness. His mother (II1) had a long history of repeated convulsions and died at the age of 33 years from status epilepticus. Her CT brain scan at that time showed bilateral basal ganglia calcification. The maternal aunt (II5) also had a history of status epilepticus and encephalopathy at the age of 20 years. Genomic DNA was extracted from peripheral blood samples using a salting out procedure.4
Muscle DNA was prepared from three 10 l,m thick formalin fixed paraffin embedded sections of the muscle biopsy tissue which measured 4 mm in diameter. The hydrated sections were digested with 20 jig of proteinase K in 100 1l of 50 mmol/l Tris buffer, pH 8-5, containing 1 mmol/l EDTA and 0 5% Tween 20, for 16 h at 37°C. The digestion mixture was heated to 95°C for 10 min to inactivate proteinase K. Ten microlitres of the heated digest was used directly for polymerase chain reaction (PCR). The primers were homologous to the nt3116-3134 (forward) and nt3353-3333 (backward) parts of the mtDNA sequence. Between 50 and 100 ng of total DNA was amplified in a 25 pl reaction mixture containing 1 x Mg-free Promega Taq DNA polymerase buffer, 200 jimol/l each dTNP, 1-5 mmol/l MgCl2, 0 5,umol/l each primer, and one unit of Taq DNA polymerase (Promega). Using an Ericomp temperature cycler the reactions were heated to 94°C for 2 min followed by 25 cycles of 60 s denaturation at 94°C, 90s annealing at 55°C, and 3 min extension at 72°C. In the final cycle, the reaction was held at the 94'C denaturation step while 2,uCi oct-32P-dCTP were added to each tube. The cycle was completed, followed by a final extension of 8 min.
Quantitative analysis of the nt3243 A--G mutation was performed according to the pub- Although the amount of mutant mtDNA can vary widely among different tissues, our results from mutation analysis of the peripheral blood samples of the MELAS family members show a good correlation with the presence ofsymptoms ( figure) . As shown in the figure, the degree of heteroplasmy varies greatly between siblings and between generations. This phenomenon is frequently observed in pedigrees that are segregating a mitochondrial DNA mutation.
The patient's brother (III2) had the second largest amount of mutant mtDNA and ragged red fibres in the muscle biopsy; however, he had had no history of convulsions over his first 16 years. The other relatives with few symptoms, II5 and III3, have lower mutant mtDNA content (24% and 27%) in the blood, and showed symptoms of status epilepticus and encephalopathy since the ages of 20 and 8 years respectively. These results indicate that the degree of heteroplasmy in blood does not always correlate with the degree of heteroplasmy in brain tissues. However, it does provide a rough guideline to the amount of mutant mtDNA that may be present in other tissues. This proved to be the case, since 3 months after the DNA analysis was performed, patient III2 developed his first episode of generalised tonic-clonic convulsion.
The diagnostic approach to mitochondrial disorders has recently been reviewed.3 For most patients suspected of defective oxidative phosphorylation, the evaluation of a muscle biopsy by means of enzyme histochemistry and electron microscopy can be useful in supporting the diagnosis. However, the absence of ragged red fibres does not exclude mitochondrial disorders and, because it is invasive, this test is not suitable for family screening. The final diagnosis would best be confirmed by biochemical or molecular genetic techniques. However, MELAS includes one or more deficiencies of respiratory chain complexes and these defects also occur in other mitochondrial diseases. Thus the lack of respiratory chain complexes is non-specific and assays of enzyme activities do not differentiate patients with suspected mitochondrial diseases phenotypically. Thrombosis is a common complication of malignant disease and pulmonary embolism is the second commonest cause of death in cancer patients.' Adenocarcinoma of the pancreas is associated with a particularly high incidence of thromboembolism. We have previously reported that the expression of the cell surface procoagulant tissue factor (TF), the physiological initiator ofblood coagulation, correlates with histological grade in this disease; normal pancreatic tissue shows no immunoreactivity whereas poorly differentiated tumours have strong immunoreactivity in nearly 80% of cases.2 This work supported our observations that the procoagulant activity in human pancreatic carcinoma cell lines is very high, varying from 14 to 6600 thromboplastin units, with at least 86% of this activity being TF dependent in each case.' These cells also possess a high prothrombinase activity, a prerequisite to efficient cell surface thrombin generation.
Thrombin is generated by tumour cells in large quantities, therefore explaining the histological observation of peritumoral fibrin deposition4 and providing a possible mechanism for the hypercoagulable state seen in cancer patients. However, thrombin possesses a number of important functions other than its role in haemostasis, including effects on endothelial cells such as promotion of arachidonic acid metabolism and release of tissue factor, von Willebrand factor, tissue plasminogen activator, and plasminogen activator inhibitor.' In tumour cells it has been shown to promote synthesis and release of urokinase plasminogen activator.6 It is also an important mitogen to normal cells such as fibroblasts and smooth muscle cells that play a key role in atherogenesis.7 Thrombin is also mitogenic to tumour cells, potentiating the proliferative response to insulin, epidermal growth factor, and transferrin. 8 Other activated serine proteases generated as a result of the activation of coagulation have roles outside normal haemostasis and are mitogenic. Of particular interest is factor Xa, the factor occupying the pivotal position in the normal coagulation pathway. Recently a specific receptor (effector cell protease receptor-l (EPR-1)) for this serine protease has been identified and cloned and shown to be of functional significance.9 In this study we have
